Three articles [21, 23, 29] (3 cohorts) reported the 2-year EFS of IDH inhibitors in patients with newly diagnosed IDH-mutated AML, and our pooled 2-year EFS rate was 29% [95% CI 0.18–0.47, I2 = 75%]. This evidence concerns the gene IDH1 and acute myeloid leukemia.